학술논문
allele burden [greater than or equal to] 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
Document Type
Report
Author
Source
Leukemia. August, 2016, Vol. 30 Issue 8, p1772, 4 p.
Subject
Language
English
ISSN
0887-6924
Abstract
Ruxolitinib, a JAKT/JAK2 tyrosine kinase inhibitor, is approved for the treatment of myeloproliferative neoplasm (MPN)-associated myelofibrosis based on the results of COMFORT-I and -II trials showing that therapy reduced splenomegaly, [...]